BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) affects more than one-third of people living with human immunodeficiency virus (HIV). Nonetheless, its natural history is poorly understood, including which patients are most likely to have a progressive disease course. METHODS: We leveraged a randomized trial of the growth hormone-releasing hormone analogue tesamorelin to treat NAFLD in HIV. Sixty-one participants with HIV-associated NAFLD were randomized to tesamorelin or placebo for 12 months with serial biopsies. RESULTS: In all participants with baseline biopsies (n = 58), 43% had hepatic fibrosis. Individuals with fibrosis had higher NAFLD Activity Score (NAS) (mean ± standard deviation [SD], 3.6 ± 2.0 vs 2.0 ± 0.8; P < .0001) and visceral fat content (mean ± SD, 284 ± 91 cm2 vs 212 ± 95 cm2; P = .005), but no difference in hepatic fat or body mass index. Among placebo-treated participants with paired biopsies (n = 24), 38% had hepatic fibrosis progression over 12 months. For each 25 cm2 higher visceral fat at baseline, odds of fibrosis progression increased by 37% (odds ratio, 1.37 [95% confidence interval, 1.03-2.07]). There was no difference in baseline NAS between fibrosis progressors and nonprogressors, though NAS rose over time in the progressor group (mean ± SD, 1.1 ± 0.8 vs -0.5 ± 0.6; P < .0001). CONCLUSIONS: In this longitudinal study of HIV-associated NAFLD, high rates of hepatic fibrosis and progression were observed. Visceral adiposity was identified as a novel predictor of worsening fibrosis. In contrast, baseline histologic characteristics did not relate to fibrosis progression.
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) affects more than one-third of people living with human immunodeficiency virus (HIV). Nonetheless, its natural history is poorly understood, including which patients are most likely to have a progressive disease course. METHODS: We leveraged a randomized trial of the growth hormone-releasing hormone analogue tesamorelin to treat NAFLD in HIV. Sixty-one participants with HIV-associated NAFLD were randomized to tesamorelin or placebo for 12 months with serial biopsies. RESULTS: In all participants with baseline biopsies (n = 58), 43% had hepatic fibrosis. Individuals with fibrosis had higher NAFLD Activity Score (NAS) (mean ± standard deviation [SD], 3.6 ± 2.0 vs 2.0 ± 0.8; P < .0001) and visceral fat content (mean ± SD, 284 ± 91 cm2 vs 212 ± 95 cm2; P = .005), but no difference in hepatic fat or body mass index. Among placebo-treated participants with paired biopsies (n = 24), 38% had hepatic fibrosis progression over 12 months. For each 25 cm2 higher visceral fat at baseline, odds of fibrosis progression increased by 37% (odds ratio, 1.37 [95% confidence interval, 1.03-2.07]). There was no difference in baseline NAS between fibrosis progressors and nonprogressors, though NAS rose over time in the progressor group (mean ± SD, 1.1 ± 0.8 vs -0.5 ± 0.6; P < .0001). CONCLUSIONS: In this longitudinal study of HIV-associated NAFLD, high rates of hepatic fibrosis and progression were observed. Visceral adiposity was identified as a novel predictor of worsening fibrosis. In contrast, baseline histologic characteristics did not relate to fibrosis progression.
Authors: G Lui; V W-S Wong; G L-H Wong; W C-W Chu; C-K Wong; I M H Yung; R Y K Wong; S-L Yeung; D K-W Yeung; C S K Cheung; H-Y Chan; H L-Y Chan; N Lee Journal: Aliment Pharmacol Ther Date: 2016-06-15 Impact factor: 8.171
Authors: Mark S Sulkowski; Shruti H Mehta; Michael S Torbenson; Yvonne Higgins; Sherilyn C Brinkley; Ruben Montes de Oca; Richard D Moore; Nezam H Afdhal; David L Thomas Journal: AIDS Date: 2007-10-18 Impact factor: 4.177
Authors: P Mulder; M C Morrison; P Y Wielinga; W van Duyvenvoorde; T Kooistra; R Kleemann Journal: Int J Obes (Lond) Date: 2015-10-26 Impact factor: 5.095
Authors: C Busca; M Sánchez-Conde; M Rico; M Rosas; E Valencia; A Moreno; V Moreno; L Martín-Carbonero; S Moreno; I Pérez-Valero; J I Bernardino; J R Arribas; J González; A Olveira; P Castillo; M Abadía; L Guerra; C Mendez; M L Montes Journal: Open Forum Infect Dis Date: 2022-06-09 Impact factor: 4.423
Authors: Lindsay T Fourman; Takara L Stanley; James M Billingsley; Shannan J Ho Sui; Meghan N Feldpausch; Autumn Boutin; Isabel Zheng; Colin M McClure; Kathleen E Corey; Martin Torriani; David E Kleiner; Colleen M Hadigan; Raymond T Chung; Steven K Grinspoon Journal: Sci Rep Date: 2021-05-18 Impact factor: 4.379
Authors: Neeti Agarwal; Claudia E Ramirez Bustamante; Huaizhu Wu; Reina Armamento-Villareal; Jordan E Lake; Ashok Balasubramanyam; Sean M Hartig Journal: Physiol Rep Date: 2022-05
Authors: Lindsay T Fourman; James M Billingsley; George Agyapong; Shannan J Ho Sui; Meghan N Feldpausch; Julia Purdy; Isabel Zheng; Chelsea S Pan; Kathleen E Corey; Martin Torriani; David E Kleiner; Colleen M Hadigan; Takara L Stanley; Raymond T Chung; Steven K Grinspoon Journal: JCI Insight Date: 2020-08-20